Adalimumab

8. Immunomodulators and antineoplastics  →  8.1. Immunomodulators for non-malignant disease

### Indication
- Rheumatoid arthritis

### INN
- Adalimumab

### Medicine type
- Biological agent

### List type
- Complementary (EML)
- (EMLc)

### Additional notes
- EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.

### Formulations
- Parenteral > General injections > SC:
  - 40 mg per 0.8 mL
  - 40 mg per 0.4 mL
  - 10 mg per 0.2 mL (EMLc)
  - 20 mg per 0.4 mL (EMLc)

### EML status history
- First added in 2019 (TRS 1021)
- Changed in 2023 (TRS 1049)

### Sex
- All

### Age
- Also recommended for children

### Therapeutic alternatives
- certolizumab pegol (ATC codes: L04AB05)
- etanercept (ATC codes: L04AB01)
- golimumab (ATC codes: L04AB06)
- infliximab (ATC codes: L04AB02)

### Patent information
- Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
  - Read more about patents.

### Tags
- Biological

Wikipedia
- Adalimumab

DrugBank
- Adalimumab

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.